불면증 치료제 시장(2026-2030년)

The global insomnia therapeutics market is forecasted to grow by USD 1288.6 mn during 2025-2030, accelerating at a CAGR of 6% during the forecast period. The report on the global insomnia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of insomnia is increasing market demand , technological advancements in diagnostics and treatment, rising healthcare expenditure and insurance coverage.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global insomnia therapeutics market is segmented as below:

By Type

• Drug
• Devices

By Distribution Channel

• Prescription
• OTC

By Drug Class

• Non-benzodiazepines
• Benzodiazepines
• Antidepressants
• Orexin receptor antagonists
• Melatonin receptor agonists

Geography

• North America
  • US
  • Canada
  • Mexico
• Asia
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the increased focus on non-pharmacological treatments as one of the prime reasons driving the global insomnia therapeutics market growth during the next few years. Also, technological advancements in sleep monitoring and tracking and growing awareness and acceptance of importance of mental health will lead to sizable demand in the market.

The report on the global insomnia therapeutics market covers the following areas:

• Global insomnia therapeutics market sizing
• Global insomnia therapeutics market forecast
• Global insomnia therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global insomnia therapeutics market vendors that include Aurobindo Pharma Ltd., BigHealth, Cipla Inc., Currax Pharmaceuticals LLC, Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Hikma Pharmaceuticals Plc, Idorsia Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Lupin Ltd., Merck and Co. Inc., Pfizer Inc., Sanofi SA, Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Vanda Pharmaceuticals Inc., Viatris Inc., Zydus Lifesciences Ltd.. Also, the global insomnia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Insomnia Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Insomnia Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Insomnia Therapeutics Market
• 6.2 Impact of Geopolitical Conflicts on Global Insomnia Therapeutics Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Drug - Market size and forecast 2025-2030
• 8.4 Devices - Market size and forecast 2025-2030
• 8.5 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Prescription - Market size and forecast 2025-2030
• 9.4 OTC - Market size and forecast 2025-2030
• 9.5 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Drug Class

• 10.1 Market segments
• 10.2 Comparison by Drug Class
• 10.3 Non-benzodiazepines - Market size and forecast 2025-2030
• 10.4 Benzodiazepines - Market size and forecast 2025-2030
• 10.5 Antidepressants - Market size and forecast 2025-2030
• 10.6 Orexin receptor antagonists - Market size and forecast 2025-2030
• 10.7 Melatonin receptor agonists - Market size and forecast 2025-2030
• 10.8 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Asia - Market size and forecast 2025-2030
  • 12.4.1 China - Market size and forecast 2025-2030
  • 12.4.2 India - Market size and forecast 2025-2030
  • 12.4.3 Japan - Market size and forecast 2025-2030
  • 12.4.4 South Korea - Market size and forecast 2025-2030
  • 12.4.5 Indonesia - Market size and forecast 2025-2030
  • 12.4.6 Thailand - Market size and forecast 2025-2030
• 12.5 Europe - Market size and forecast 2025-2030
  • 12.5.1 Germany - Market size and forecast 2025-2030
  • 12.5.2 UK - Market size and forecast 2025-2030
  • 12.5.3 France - Market size and forecast 2025-2030
  • 12.5.4 Italy - Market size and forecast 2025-2030
  • 12.5.5 Spain - Market size and forecast 2025-2030
  • 12.5.6 The Netherlands - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing prevalence of insomnia is increasing market demand
  • Technological advancements in diagnostics and treatment
  • Rising healthcare expenditure and insurance coverage
• 13.2 Market challenges
  • Lack of awareness of insomnia as disease
  • Concerns about safety and efficacy of insomnia therapeutics
  • Regulatory and reimbursement issues in insomnia therapeutics
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Increased focus on non-pharmacological treatments
  • Technological advancements in sleep monitoring and tracking
  • Growing awareness and acceptance of importance of mental health

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
• 15.5 BigHealth
  • BigHealth - Overview
  • BigHealth - Product / Service
  • BigHealth - Key offerings
  • SWOT
• 15.6 Currax Pharmaceuticals LLC
  • Currax Pharmaceuticals LLC - Overview
  • Currax Pharmaceuticals LLC - Product / Service
  • Currax Pharmaceuticals LLC - Key offerings
  • SWOT
• 15.7 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.8 Eisai Co. Ltd.
  • Eisai Co. Ltd. - Overview
  • Eisai Co. Ltd. - Business segments
  • Eisai Co. Ltd. - Key offerings
  • Eisai Co. Ltd. - Segment focus
  • SWOT
• 15.9 Idorsia Pharmaceuticals Ltd.
  • Idorsia Pharmaceuticals Ltd. - Overview
  • Idorsia Pharmaceuticals Ltd. - Product / Service
  • Idorsia Pharmaceuticals Ltd. - Key news
  • Idorsia Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.10 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.11 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.12 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.13 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.14 Sumitomo Pharma Co. Ltd.
  • Sumitomo Pharma Co. Ltd. - Overview
  • Sumitomo Pharma Co. Ltd. - Business segments
  • Sumitomo Pharma Co. Ltd. - Key offerings
  • Sumitomo Pharma Co. Ltd. - Segment focus
  • SWOT
• 15.15 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.16 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.17 Vanda Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc. - Overview
  • Vanda Pharmaceuticals Inc. - Product / Service
  • Vanda Pharmaceuticals Inc. - Key news
  • Vanda Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.18 Zydus Lifesciences Ltd.
  • Zydus Lifesciences Ltd. - Overview
  • Zydus Lifesciences Ltd. - Business segments
  • Zydus Lifesciences Ltd. - Key news
  • Zydus Lifesciences Ltd. - Key offerings
  • Zydus Lifesciences Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations